Arbutus Biopharma CORP (ABUS) Institutional Investor Snapshot (179 Funds, Q2 2026)

ABUS ranks #3283 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ABUS is a top-conviction position for Whitefort Capital Management, LP — at 18.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ABUS belongs to California State Teachers Retirement System, but the position matters far more to Whitefort Capital Management, LP, who has 18.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Two Seas Capital LP has added to its ABUS position for two straight quarters, increasing it by $31.1M to reach $91.7M today.

Morgan Stanley has trimmed its ABUS position for two straight quarters, cutting it by $43.5M while still holding $85.0M.

ABUS is up 0.2% today, and institutions have been net buyers of $41.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ABUS posted net income of $153.1M over the trailing twelve months, and currently trades at a P/E of 6.4.

• Profitable — net income of $153.1M over the trailing twelve months
• Revenue grew 1078.8% year over year
• Net income improved year over year, from -$54.3M to $153.1M
• Operating cash flow was negative, using $39.6M in cash
• Current ratio of 15.73x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.24x equity — within a conventional range